Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effect of Testosterone Replacement Therapy on Quality of Life and Sexual Function in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency: Results From a Randomized Double-blind Trial

Research output: Contribution to journalJournal articlepeer-review

View graph of relations

BACKGROUND: Testicular cancer (TC) treatment leaves many patients with low levels of testosterone. While most TC patients with low testosterone (< - 2 SD) and hypogonadal symptoms will initiate testosterone replacement therapy (TRT), the role of TRT in patients with mild Leydig cell insufficiency, defined as elevated luteinizing hormone in combination with borderline low testosterone, is unknown. To clarify if TRT improves symptoms of depression and anxiety, sexual function, fatigue, and quality of life in TC survivors with mild Leydig cell insufficiency.

MATERIALS AND METHODS: In total, 69 men aged between 18 and 65 years with mild Leydig cell insufficiency after TC treatment were randomized 1:1 to 12 months daily transdermal testosterone (maximum dose 40 mg/daily) vs. placebo. Patient reported anxiety, depression, sexual function, fatigue, and overall quality of life were assessed at baseline, after 6- and 12 months treatment, and 3 months post-treatment using validated questionnaires.

RESULTS: After 12 months of treatment, median luteinizing hormone and median free testosterone were normalized in the testosterone group. Compared to placebo, TRT was not associated with statistically significant improvement of symptoms of anxiety and depression, sexual function, fatigue, and overall quality of life. Testosterone replacement therapy did not improve anxiety, depression, sexual function, fatigue, or overall quality of life in patients with mild Leydig cell insufficiency compared to placebo.

CONCLUSION: Routine TRT in TC survivors with mild Leydig cell insufficiency to improve sexual function and quality of life cannot be generally recommended. The findings should preferably be validated in a larger cohort.

Original languageEnglish
JournalClinical Genitourinary Cancer
Volume20
Issue number4
Pages (from-to)334-343
Number of pages10
ISSN1938-0682
DOIs
Publication statusPublished - Aug 2022

Bibliographical note

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

    Research areas

  • Adolescent, Adult, Aged, Fatigue, Hormone Replacement Therapy, Humans, Leydig Cells, Luteinizing Hormone, Male, Middle Aged, Neoplasms, Germ Cell and Embryonal, Quality of Life, Survivors, Testicular Neoplasms/drug therapy, Testosterone/therapeutic use, Young Adult

ID: 77927421